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ABSTRACT  
Objective: This study was aimed to evaluate the role of genistein or 4',5,7-trihydroxyisoflavone as a phytoestrogen in the treatment of estrogen 
deficiency-induced neuroinflammatory. The specific objectives of this study were to determine the anti-neuroinflammatory effect of genistein 
through measurement of MHC II and Arg1 expressions on microglia HMC3 cell line, as well as to prove that the effect occurs in an ER-dependent 
manner, through the measurement of free-ERβ expression. 
Methods: The cells were cultured in 24-well microplates, induced with 10 ng IFN-γ, and incubated for 24 h to activate the cell to M1 phenotype 
which has pro-inflammatory characteristics. Genistein with a concentration of 50 μM was added to the cells. The expression of MHC II, Arg1, and 
free-ERβ as markers was tested through an immunocytochemistry method and measured using the CLSM instrument. In silico approach was also 
conducted to determine the interaction between genistein and ERβ, compared to 17β-estradiol. Genistein structure was prepared with Avogadro 
1.0.1, and molecular docking was done using PyRx 0.8 software. Biovia Discovery Studio Visualizer 2016 was used to visualize the structure of 
genistein against 3OLS protein. The physicochemical characteristics of genistein were analyzed using the SwissADME web tool. 
Results: Genistein can decrease MHC II expression and increase Arg1 expression in microglia HMC3 cells compared to negative controls (p<0.005), 
with expression value of 472.577±26.701 AU and 114.299±6.578 AU. But, genistein cannot decrease the free-ERβ expression in cells (p<0.005). The 
results of in silico analysis showed that genistein is an ERβ agonist. 
Conclusion: Genistein shows anti-neuroinflammatory effects by decreasing the MHC II expression and increasing Arg1 expression in the microglia 
HMC3 cell line. However, this effect does not occur through the binding of genistein to ERβ, but it is likely to occur through the binding of genistein 
with other types of ER. 
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INTRODUCTION  
The global prevalence of neurodegenerative diseases has been 
increasing in recent decades [1]. One of the main causes of 
neurodegenerative diseases is neuroinflammatory. For postmenopausal 
women, neuroinflammatory is triggered by estrogen deficiency. In the 
other words, estrogen deficiency triggers postmenopausal women to be 
prone to neuroinflammatory, which can causes some neurodegenerative 
disorders [2-4]. In neuroinflammatory, there is an increase of the 
number of microglia cells that are activated in the M1 polarity state 
which has pro-inflammatory characteristics due to estrogen deficiency. 
The increasing of activated microglia cells then causes an increase in 
inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, tumor 
necrosis factor-α (TNF-α), and nitric oxide (NO), as well as major 
histocompatibility complex II (MHC II) [5, 6]. Continuous M1 polarity 
state activation of microglia cells can cause prolonged inflammation and 
induces hippocampal neuron cell death leading to decreased cognitive 
function [7-9].  
Inhibition of neuroinflammatory progression can be conducted to 
prevent neurodegenerative diseases. The logic method is to provide 
estrogen replacement compounds to activate microglia cells towards 
the M2 polarity state, which has anti-inflammatory characteristics. 
Activation of microglia cells in M1 polarity causes pro-inflammatory 
conditions that are characterized by an increase of inflammatory 
cytokines. In contrast, activation of microglia cells in M2 polarity 
causes an anti-inflammatory condition characterized by decrease of 
inflammatory cytokines, as well as an increase in the expression of IL-
10, IL-13, T-cell growth factor-β (TGF-β), and arginase 1 (Arg1) [7-9]. 
Phytoestrogens are compounds derived from plants which have 
similar structure to estrogen. Biologically, they can replace the 
function of estrogen in maintaining homeostasis in the brain, both in 
conjunction with estrogen receptors (ER-dependent) or not in 
conjunction with the receptors (ER-independent) [10]. Thus, using 
phytoestrogens can be an alternative treatment for estrogen 
deficiency-induced neuroinflammatory [11]. Genistein or 4',5,7-
trihydroxyisoflavone with molecular formula C15H10O5 (fig. 1) is an 
example of phytoestrogens. Genistein is a plant naturally occurring 
compound belonging to the isoflavone group. This compound can be 
found in various species of Leguminoceae or Fabaceae [12]. 
Genistein was known to be able to bind estrogen receptors (ER) and 
produce many estrogenic effects [13-16], thus, it is potential to be 
used as an agent of neuroinflammatory therapy. 
 
 
Fig. 1: Molecular structure of genistein 
 
This research aimed to determine the anti-neuroinflammatory effect 
of genistein through measurement of MHC II and Arg1 expression on 
human microglia clone 3 (HMC3) cell line (ATCC® CRL-3304™) [17] 
in an in vitro testing, as well as to know that the effect occurs in an 
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ER-dependent manner, through the measurement of free-ERβ 
expression. The estrogen deficiency condition was created by 
induction of interferon-γ (IFN-γ) to the microglia HMC3 cells culture, 
and the measurement of markers was done using 
immunocytochemistry method and confocal laser scanning 
microscope (CLSM) instrument. 
In addition to in vitro testing, we also confirmed the interaction 
pattern between genistein and the estrogen receptor in silico, by 
conducting molecular docking between genistein and 3OLS protein-
containing histidine, glutamine and arginine on the active site of this 
protein. Research on genistein as a neuroprotective agent has been 
done quite a lot, but the effect of genistein as a neuroprotective 
through an anti-neuroinflammatory mechanism in HMC3 microglia 
cells has never been done before. 
MATERIALS AND METHODS  
Materials  
The microglia HMC cell line was purchased from American Type 
Culture Collection (ATCC® CRL-3304™) Manassas, USA [17]. 
Genistein, eagle's minimum essential medium (EMEM), dimethyl 
sulfoxide (DMSO), paraformaldehyde (PFA), fetal bovine serum 
(FBS), phosphate buffer saline (PBS), serum bovine albumin (BSA), 
Tween 80, IFN-γ, Triton X100, anti-rabbit secondary antibody 
fluorescein isothiocyanate (FITC), anti-mouse secondary antibody 
rhodamine, were purchased from Sigma-Aldrich, Missouri, USA; 
penicillin, streptomycin, anti-rabbit MHC II primary antibody 
(ab114224), anti-rabbit ERβ primary antibody (ab3576), were 
purchased from Abcam, Boston, USA; anti-mouse Arg1 primary 
antibody (sc-166920) was purchased from Santa Cruz 
Biotechnology, California, USA. 
Cell culture 
Preparation of cell culture was conducted according to a procedure 
developed by Central Laboratory of Life Sciences, Universitas 
Brawijaya, Indonesia [18-20]. Microglia HMC3 cell line was cultured 
in a 25 cm2 flask containing±250.000 cells with a complete medium 
containing 5 ml EMEM, 10% FBS, and 1% penicillin-streptomycin. 
The cells culture was then incubated in a 5% CO2 incubator at 37 °C 
for 6 d, until the cells growth reached 80% confluent in the flask. 
Genistein solution 
A 50 μM genistein sample solution was prepared by mix 40 μl of 1 
mmol genistein solution with 0.8 ml complete medium containing 5 
ml EMEM, 10% FBS, and 1% penicillin-streptomycin. 
Measurement of MHC II, Arg1, and free-ERβ 
The effects of genistein on microglia HMC3 cell lines were measured 
according to a procedure developed by Central Laboratory of Life 
Sciences, Universitas Brawijaya, Indonesia [19-20]. After cultured cells 
reach 80% confluence, then the induction of IFN-γ was performed. 10 ng 
IFN-γ was added into the cells, and the culture was incubated for 24 h. 
The cultured cells were then rinsed with PBS and treated with 50 μM 
genistein for 48 h. The cells then rinsed again with PBS and fixed with 
4% PFA, Triton X100, BSA, and anti-rabbit MHC II primary antibody for 
single staining methods. After the previous procedure, a double staining 
method was performed in different 24-well microplates with anti-mouse 
Arg1 primary antibody and anti-rabbit ERβ primary antibody. The cells 
were then incubated at 4 °C overnight. As the final step of the 
procedures, an anti-rabbit secondary antibody FITC and anti-mouse 
secondary antibody rhodamine were added before the cells were 
analyzed using a CLSM instrument at 488 nm and 543 nm. 
In silico evaluation 
The three-dimensional structure of estrogen receptor (ERβ) was 
obtained from Protein Data Bank (http://www.rcsb.org) with code 3OLS 
[21]. Initial preparation was done to separate the natural ligand of ERβ–
that is 17β-estradiol-from the protein using Biovia Discovery Studio 
Visualizer 2016. The natural ligand and genistein molecular structures 
were prepared with Avogadro 1.90.0 for energy optimization by using 
the MMF94s method. Molecular docking and simulation of the docking 
were conducted using PyRx 0.8 software [22, 23]. The complex of 
receptor-ligand obtained from docking simulation was visualized using 
Biovia Discovery Studio Visualizer 2016. Further analysis was done 
using the SwissADME web tool to predict the physicochemical 
properties of genistein and the natural ligand. 
RESULTS 
Visualization of marker expression in microglia HMC3 cells can be seen 
in fig. 2 and fig. 3, while the results of the analysis of marker expression 
are as shown in table 1. In fig. 2 and fig. 3, the treatment of genistein 
decreased MHC II expression significantly compared to negative control 
with p=0.002. The decrease in MHC II expression was indicated by the 
decrease in the fluorescence intensity of the microglia HMC3 cell line. 
The induction of genistein increases Arg1 expression significantly 
compared to negative control with p<0.001, as well as increases the free-
ERβ expression significantly compared to negative control with p<0.001. 
The increase in Arg1 expression was indicated by an increase in the red 
color intensity of microglia HMC3 cell line, while the increase in free-ERβ 
expression was indicated by an increase in the green color intensity of 
the microglia HMC3 cell line. 
 
 
Fig. 2: The expression of MHC II, Arg1 and Free-ERβ after genistein induction in microglia HMC3 cell line. Each value is expressed as 
mean±SD. Significant differences compared to a negative control (*) at p<0.05 
 
Table 1: The expression value of MHC II, Arg1, and free-ERβ in arbitrary unit (AU) after genistein induction in microglia HMC3 cell line 
Groups MHC II (AU) Arg1 (AU) Free-ERβ (AU) 
Negative control 1149.399±25.810 47.080±6.799 287.735±26.107 
Genistein 472.577±26.701* 114.299±6.578* 553.295±29.694* 
Note: Each value is expressed as mean±SD. Significant differences compared to negative control (*) at p<0.05. 
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Fig. 3: The immunofluorescence visualization of markers in microglia HMC3 cell lines. (A) Negative control; (B) Genistein: (1) MHC II 
expression, (2) Arg1 expression, (3) Free-ERβ expression 
 
The results of in silico evaluation on the interaction of both genistein 
and natural ligand (17β-estradiol) with the ERβ can be seen in table 
2. A comparison of pharmacophore distance (bond distance) and 
amino acid bonds between 3OLS protein and 17β-estradiol and 
genistein is as shown in fig. 4. Compounds or ligands are categorized 
as agonists of the 17β-estradiol if they have a bond distance and 
pharmacophore groups similar to 17β-estradiol. Besides that, they 
should bind the same amino acids in the 3OLS protein as 17β-
estradiol. That is, if it has a bond distance of about 10.862 Å, and has 
one pharmacophore group that binds His 475, and another 
pharmacophore group binds Glu 305 or Arg 346. These results 
indicate that genistein is an ERβ agonist like 17β-estradiol; thus, it 
has a high potential to be used as a drug in neuroinflammatory 
therapy.
 














Lipinski’s rule of five 
BM 
(g/mol) 




Genistein -8.6 0.000 His475 (Hydrogen) 
Glu305 (Hydrogen) 
Arg 346 (Unfavorable) 
12.136 90.90 270.24 0.52 5 3 
17β-
estradiol 
-10.5 0.000 His475 (Hydrogen) 
Glu305 (Hydrogen) 
Arg 346 (Hydrogen) 
10.862 40.46 272.38 3.53 2 2 
Criteria: TPSA≤140; MW ≤500g/mol; log P ≤5; H-bond acceptors N or O ≤ 10; H-bond donors NH or OH ≤5. 
 
 
Fig. 4: (A) Binding mode of 17β-estradiol bond with the amino acid in the 3OLS protein. The 17β-estr adiol binds amino acid with a 
pharmacophore distance (bond distance) of 10.862 Å, and binds his 475, Glu 305, and Arg 346 with hydrogen bonds. (B) Genistein binds 
amino acid with bond distance of 12.135 Å, and binds His 475 and Glu 305 with hydrogen bonds, and binds Arg 346 with an unfavorable bond 
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DISCUSSION 
The anti-neuroinflammatory effect of genistein occurs through the 
induction of inhibition of HMC3 microglia cells activation to a pro-
inflammatory state (M1 polarity), which is characterized by 
inhibition of MHC II expression. As well as induction of increase of 
HMC3 microglia cells activation to an anti-inflammatory state (M2 
polarity), which is characterized by an increase in Arg1 expression. 
Anti-neuroinflammatory activity was predicted to occur in an ER-
dependent manner, so we also examined it using the ERβ as marker. 
In this study, the model of inflammation-induced estrogen deficiency 
was made by induction of IFN-γ [17, 24, 25]. IFN-γ binds toll-like 
receptor 4 (TLR4) and activates nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB). Both estrogen deficiency and 
induction of IFN-γ on microglia HMC3 cells were known to be able to 
activate the cells to M1 polarity conditions, where active microglia 
HMC3 cells have pro-inflammatory characteristics [7, 9]. 
Anti-neuroinflammatory activity occurs when genistein was given to 
microglia HMC3 cells as a treatment and replaces the function of 
estrogen in regulating the activity of the cell [11, 26-28]. In this 
process, there was an activation of microglia HMC3 cells to M2 
polarity condition, where active microglia HMC3 cells have anti-
inflammatory characteristics [7]. The increase of bonding between 
genistein and ERβ in the ER-dependent nuclear-initiated estrogen 
signaling pathway can activate ERβ in the cytoplasm to translocate 
in the nucleus, which causes several mechanisms such as inhibition 
of inhibitor of kappa B kinase (IκK) activation, inhibition of 
phosphorylation inhibitor of kappa B (IκB), inhibition of NF-κB 
activation, and induces down-regulation of the human leukocyte 
antigen B27 (HLA-B27) gene, which causes a decrease in the 
production of pro-inflammatory cytokines while production of anti-
inflammatory agents is increase [2, 3, 5, 10]. 
The prediction of genistein activity can be carried out with in silico 
analysis. This method assists in simple predictions by correlating the 
structure and physicochemical properties with application analysis 
regarding its potential as medicine [29]. In silico studies were used to 
predict the activity of genistein in binding to ERβ at the molecular level, 
whether genistein is an ERβ agonist and is able to provide estrogenic 
effects such as 17β-estradiol or not. This in silico results were then used 
to explain the mechanism that occurs in the in vitro results. 
The physicochemical properties of genistein were analyzed in silico 
based on the criteria of topological polar surface area (TPSA) value 
and Lipinski’s rule of five. TPSA is a value that describes the ability 
of a compound to penetrate the membrane. The compounds are 
categorized as being able to penetrate the cell membrane if it has a 
TPSA value<140Å² [30]. From the physicochemical analysis, it was 
shown that genistein has TPSA value<140 Å², so it meets the 
criterion. The results of physicochemical analysis also indicate that 
genistein meets the criteria of Lipinski’s rule of five, so it has the 
potential to be developed as an oral drug [31, 32]. 
In connecting the results of in vitro and in silico studies, we found 
something interesting. In the results of measuring the expression of 
Arg1 and MHC II in vitro, genistein has been shown to have anti-
neuroinflammatory activity. Based on literature study and in silico 
results, this anti-neuroinflammatory activity occurs in an ER-
dependent manner in which genistein bind to the ER. However, in 
vitro ERβ measurements showed that genistein could not increase 
the expression of free ER compared to control, that means genistein 
did not bind significantly to ERβ. Through a literature study, we 
found that genistein can bind to G-protein coupled estrogen receptor 
(GPER) with an effective and high-affinity bonding, better than to 
ERβ [33, 34]. Thus, the activity of decreasing MHC II expression and 
increasing Arg1 by genistein is likely caused by the binding of 
genistein to GPER. In microglia cells and neurons, GPER is highly 
expressed and is responsible for ER-dependent mechanisms of non-
classical (or non-genomic) pathways [35, 36], such as anti-
neuroinflammatory activity. 
CONCLUSION 
Genistein shows anti-neuroinflammatory effects by decreasing the 
MHC II expression and increasing Arg1 expression in microglia 
HMC3 cell line, but the effect seems not to occur through the binding 
of genistein to ERβ. However, further study about the molecular 
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